Keane N M, Price P, Lee S, Almeida C A, Stone S F, James I, French M A
Department of Clinical Immunology and Biochemical Genetics, Royal Perth Hospital, Perth, WA, Australia.
HIV Med. 2004 Nov;5(6):407-14. doi: 10.1111/j.1468-1293.2004.00245.x.
To define the level of pathogen-specific immune reconstitution persisting over 3 to 5 years of highly active antiretroviral therapy (HAART) in HIV-infected patients who began therapy with CD4 T-cell counts below 50 cells/microL.
Cytomegalovirus (CMV)-specific T-cell responses were analysed in adult HIV-1-infected patients with nadir CD4 T-cell counts below 50 cells/microL before HAART. CMV-specific CD4 T-cell responses were measured by interferon-gamma enzyme-linked immunospot assay (ELISpot assay), lymphoproliferation and interferon-gamma levels in cell culture supernatants.
CD4 T-cell responses to CMV were low in untreated patients and remained low during the first year on HAART, but increased progressively to levels similar to those found in HIV-seronegative CMV-seropositive controls at 3 years. Responses then declined markedly and at 5 years were lower than controls. This could not be explained by changes in CD4 or CD8 T-cell counts or plasma HIV RNA levels. Interferon-gamma and interleukin-5 responses to a mitogen were maintained or elevated.
CMV-specific CD4 T-cell responses were found to decline after 3-5 years on HAART and may provide inadequate long-term protection against CMV disease in patients who are severely immunodeficient prior to treatment.
确定在开始治疗时CD4 T细胞计数低于50个/微升的HIV感染患者中,高效抗逆转录病毒治疗(HAART)3至5年后持续存在的病原体特异性免疫重建水平。
对HAART治疗前最低点CD4 T细胞计数低于50个/微升的成年HIV-1感染患者的巨细胞病毒(CMV)特异性T细胞反应进行分析。通过干扰素-γ酶联免疫斑点试验(ELISpot试验)、淋巴细胞增殖和细胞培养上清液中的干扰素-γ水平来测量CMV特异性CD4 T细胞反应。
未经治疗的患者对CMV的CD4 T细胞反应较低,在HAART治疗的第一年仍保持较低水平,但在3年时逐渐增加至与HIV血清阴性CMV血清阳性对照相似的水平。然后反应明显下降,在5年时低于对照。这无法用CD4或CD8 T细胞计数或血浆HIV RNA水平的变化来解释。对有丝分裂原的干扰素-γ和白细胞介素-5反应保持或升高。
发现HAART治疗3至5年后CMV特异性CD4 T细胞反应下降,对于治疗前严重免疫缺陷的患者,可能无法提供足够的长期保护以预防CMV疾病。